A Phase 1 trial of the poly(ADP-ribose) polymerase inhibitor olaparib (AZD2281) in combination with the anti-angiogenic cediranib (AZD2171) in recurrent epithelial ovarian or triple-negative breast cancer.

A Phase 1 trial of the poly(ADP-ribose) polymerase inhibitor olaparib (AZD2281) in combination with the anti-angiogenic cediranib (AZD2171) in recurrent epithelial ovarian or triple-negative breast cancer. Eur J Cancer. 2013 Sep; 49(14):2972-8.

View in: PubMed

subject areas

Administration, Oral
Adult
Aged
Antineoplastic Combined Chemotherapy Protocols
Breast Neoplasms
Capsules
Diarrhea
Dose-Response Relationship, Drug
Drug Administration Schedule
Fatigue
Female
Humans
Middle Aged
Nausea
Neoplasm Recurrence, Local
Neoplasms, Glandular and Epithelial
Ovarian Neoplasms
Phthalazines
Piperazines
Poly(ADP-ribose) Polymerase Inhibitors
Quinazolines
Receptor, ErbB-2
Receptors, Estrogen
Receptors, Progesterone
Receptors, Vascular Endothelial Growth Factor
Tablets
Treatment Outcome

authors with profiles

Gini Fleming